NCT06365853 2025-12-18
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie
Phase 2 Recruiting
AbbVie
Vanderbilt-Ingram Cancer Center
University Health Network, Toronto